Company Filing History:
Years Active: 2019-2025
Title: Michael Lutteropp: Innovator in Immunotherapy
Introduction
Michael Lutteropp is a distinguished inventor based in Bergisch Gladbach, Germany. He has made significant contributions to the field of immunotherapy, particularly in reducing side effects associated with cancer treatments. With a total of six patents to his name, Lutteropp's work is at the forefront of medical innovation.
Latest Patents
Lutteropp's latest patents focus on enhancing the efficacy of immunotherapy while minimizing adverse effects. One notable patent involves a system for preventing or reducing side effects in patients undergoing immunotherapy, specifically targeting the removal of diseased cells that express a target antigen. This system utilizes genetically modified hematopoietic cells, which are engineered to either not express the target antigen or express it in a modified form. Another significant patent addresses the use of CAR T or CAR NK cells combined with hematopoietic cells that have a modified or deleted target antigen. This invention aims to reduce the side effects of antigen-recognizing receptors against non-target cells in individuals undergoing treatment.
Career Highlights
Throughout his career, Lutteropp has worked with prominent companies in the biotechnology sector, including Miltenyi Biotec B.V. & Co. KG and Miltenyi Biotec GmbH. His experience in these organizations has allowed him to develop and refine his innovative approaches to immunotherapy.
Collaborations
Lutteropp has collaborated with notable colleagues in his field, including Anne Richter and Andrew Kaiser. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.
Conclusion
Michael Lutteropp is a pioneering inventor whose work in immunotherapy is making a significant impact on cancer treatment. His innovative patents and collaborations highlight his commitment to improving patient outcomes and reducing treatment side effects.